导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.79% | 1044/4700 |
| 近一周 | -1.07% | 1584/5371 |
| 近一月 | -3.01% | 2068/5328 |
| 近一季 | -6.22% | 2296/5140 |
| 近半年 | -0.94% | 1598/4839 |
| 近一年 | 11.45% | 1012/4338 |
| 近两年 | 85.84% | 756/2925 |
| 近三年 | 53.25% | 513/2229 |
| 成立以来 | 148.96% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.90% 1413/4961 |
20.01% 1260/5312 |
- - |
- - |
| 2025 | 36.88% 924/4813 |
4.52% 920/3635 |
2.93% 1255/4076 |
25.27% 1408/4524 |
1.57% 1321/4813 |
| 2024 | 9.37% 1474/3463 |
-1.17% 1190/2808 |
-3.77% 1417/3014 |
14.37% 1990/3129 |
0.55% 1199/3463 |
| 2023 | -5.59% 754/2656 |
4.51% 934/2280 |
-2.78% 667/2385 |
-3.15% 856/2515 |
-4.06% 856/2655 |
| 2022 | -16.05% 446/2207 |
-10.90% 452/1919 |
3.52% 1138/2016 |
-10.26% 371/2113 |
1.42% 1277/2208 |
| 2021 | 25.96% 104/1822 |
1.98% 235/1255 |
9.86% 516/1330 |
7.59% 177/1466 |
4.50% 327/1822 |
| 2020 | 40.72% 305/1250 |
-1.24% 211/1028 |
19.26% 304/1067 |
13.46% 318/1164 |
5.30% 793/1184 |
| 2019 | 33.75% 424/1092 |
29.46% 273/739 |
-6.35% 497/788 |
1.73% 363/850 |
8.44% 317/918 |
| 2018 | -25.69% 361/834 |
- - |
-11.13% 347/631 |
-7.16% 436/660 |
-9.81% 165/682 |
| 2017 | 6.79% 329/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 中金中证500A VS. 长安沪深300非周期A(740101) |